Boughton Soleil sold $101K of HIMS
Boughton Soleil (Chief Legal Officer) sold 3,461 shares of Hims & Hers Health, Inc. (HIMS) at $29.06 ($0.10M total) on 2026-10-14 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure confirms an insider sale executed under a pre-arranged 10b5-1 plan, which generally reduces the probability that the trade reflects new, material nonpublic information.
Market read
Traders may note the insider sale for sentiment, but the 10b5-1 structure makes it less likely to drive a fundamental repricing.
What to watch
The article provides only the sale details, not any concurrent buy activity, and does not indicate whether the executive’s broader trading pattern is accelerating or consistent.
Background
The article is an SEC Form 4 insider transaction disclosure for Hims & Hers Health, Inc.
Ticker impact
Hims & Hers Health disclosed a Form 4 showing Chief Legal Officer Boughton Soleil sold 3,461 shares at $29.06 on 2026-10-14 under a 10b5-1 plan.
Likely limited near-term impact as the sale is explicitly under a 10b5-1 plan, with any effect more about sentiment than fundamentals.
The filing is a primary SEC Form 4 and the transaction is coded as an open-market sale with a stated pre-arranged 10b5-1 plan, reducing the likelihood of an information-driven signal.
Market effects
No clear sector read-through from a single 10b5-1 insider sale.
None.
None.
Counterpoint
Even with 10b5-1, repeated insider selling can coincide with executives de-risking ahead of personal liquidity needs, which some traders may still interpret as bearish.
Key entities
- issuerHims & Hers Health, Inc.
US-listed company whose insider transaction was disclosed on Form 4.
- insiderBoughton Soleil
Chief Legal Officer who sold shares under a 10b5-1 plan.
